Hepatitis C virus NS3/4a protease inhibitors.
暂无分享,去创建一个
[1] L. Vrang,et al. In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor , 2009, Antimicrobial Agents and Chemotherapy.
[2] Brad J. Wood,et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study , 2015, The Lancet.
[3] Brian L. Pearlman,et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study , 2014, The Lancet.
[4] Steven R. LaPlante,et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus , 2003, Nature.
[5] Qihong Huang,et al. A Twenty-Eight-Day Mechanistic Time Course Study in the Rhesus Monkey with Hepatitis C Virus Protease Inhibitor BILN 2061 , 2011, Toxicologic pathology.
[6] R. Cortese,et al. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. , 1998, Biochemistry.
[7] T. Asselah,et al. Fibrosis and disease progression in hepatitis C , 2002, Hepatology.
[8] M. Katharine Holloway,et al. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. , 2008, Journal of the American Chemical Society.
[9] B. Brandhuber,et al. Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. , 2009, Biochemistry.
[10] T. Berg,et al. Expert opinion on the treatment of patients with chronic hepatitis C , 2009, Journal of viral hepatitis.
[11] Bin Wang,et al. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. , 2014, Journal of medicinal chemistry.
[12] J. G. Taylor,et al. GS‐9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double‐blind, dose‐ranging phase 1 study , 2016, Journal of viral hepatitis.
[13] Adam T. Gates,et al. MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants , 2012, Antimicrobial Agents and Chemotherapy.
[14] M. Rudd,et al. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. , 2010, Journal of medicinal chemistry.
[15] V. de Lédinghen,et al. Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future? , 2015, PloS one.
[16] D. Hazuda,et al. Sustained Viral Response in a Hepatitis C Virus-Infected Chimpanzee via a Combination of Direct-Acting Antiviral Agents , 2010, Antimicrobial Agents and Chemotherapy.
[17] Tom Chu,et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial , 2010, The Lancet.
[18] A. Molla,et al. In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450 , 2014, Antimicrobial Agents and Chemotherapy.
[19] Rebecca T. Ruck,et al. Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor. , 2016, ACS medicinal chemistry letters.
[20] A. Good,et al. Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. , 2014, Journal of medicinal chemistry.
[21] T. Asselah,et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial , 2015, The Lancet.
[22] A. Kwong,et al. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. , 2006, Infectious disorders drug targets.
[23] B. Samuelsson,et al. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. , 2014, Journal of medicinal chemistry.
[24] D. Lavanchy,et al. The global burden of hepatitis C , 2009, Liver international : official journal of the International Association for the Study of the Liver.
[25] M. Rudd,et al. Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor. , 2012, ACS medicinal chemistry letters.
[26] M. Houghton,et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.
[27] Jean-Michel Pawlotsky,et al. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. , 2016, Gastroenterology.
[28] R. D. de Knegt,et al. Pharmacokinetics and Antiviral Activity of Phx1766, a Novel HCV Protease Inhibitor, Using An Accelerated Phase I Study Design , 2012, Antiviral therapy.
[29] C. Rice,et al. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites , 1993, Journal of virology.
[30] A. Agarwal,et al. Rapid and Sharp Decline in HCV upon Monotherapy with Ns3 Protease Inhibitor, Ach-1625 , 2012, Antiviral therapy.
[31] Catherine Caillet,et al. Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320. , 2015, Bioorganic & medicinal chemistry letters.
[32] Qi Gao,et al. The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. , 2014, Journal of medicinal chemistry.
[33] M. Murcko,et al. Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide , 1996, Cell.
[34] Weiying Yang,et al. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: , 2006, Journal of medicinal chemistry.
[35] Qian Huang,et al. P2‐Quinazolinones and Bis‐Macrocycles as New Templates for Next‐Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK‐2748 and MK‐6325 , 2015, ChemMedChem.
[36] Charles M. Rice,et al. Unravelling hepatitis C virus replication from genome to function , 2005, Nature.
[37] T. Hassanein,et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study , 2015, The Lancet.
[38] M. Garneau,et al. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). , 2010, Journal of medicinal chemistry.
[39] Weiying Yang,et al. Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor. , 2010, ACS medicinal chemistry letters.
[40] J. Kort,et al. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection , 2015, Antimicrobial Agents and Chemotherapy.
[41] W. Delaney,et al. Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. , 2012, Bioorganic & medicinal chemistry letters.
[42] Tara L. Kieffer,et al. Hepatitis C virus drug resistance–associated substitutions: State of the art summary , 2015, Hepatology.
[43] K. Reddy,et al. GrazoprevirElbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection , 2015, Annals of Internal Medicine.
[44] P. Simmonds,et al. Genetic diversity and evolution of hepatitis C virus--15 years on. , 2004, The Journal of general virology.
[45] Bradley C Doak,et al. How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets. , 2016, Journal of medicinal chemistry.
[46] D. Lamarre,et al. Peptide-based inhibitors of the hepatitis C virus serine protease. , 1998, Bioorganic & medicinal chemistry letters.
[47] T. Appleby,et al. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease. , 2012, Bioorganic & medicinal chemistry letters.
[48] M. Rudd,et al. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease. , 2008, Angewandte Chemie.
[49] O. Weiland,et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. , 2014, Gastroenterology.